Skip to main content
. 2014 Apr 26;6(4):205–212. doi: 10.4330/wjc.v6.i4.205

Table 1.

Baseline characteristics by carbohydrate antigen 125 and N-terminal pro-brain natriuretic peptide class

Variable CA125 < 60 CA125 > 60 CA125 < 60 CA125 > 60 P
NT-proBNP < 3100 NT-proBNP < 3100 NT-proBNP > 3100 NT-proBNP > 3100
(n = 95, 61%) (n = 17, 11%) (n = 24, 15%) (n = 20, 13%)
Male 55 (58%) 11 (65%) 19 (79%) 14 (70%) 0.240
Age 71 ± 12 69 ± 10 76 ± 12 73 ± 15 0.309
Hypertension 73 (77%) 10 (59%) 18 (75%) 14 (70%) 0.471
Diabetes 38 (40%) 7 (41%) 11 (46%) 8 (40%) 0.964
Dyslipidemia 46 (48%) 5 (29%) 11 (46%) 7 (35%) 0.406
Atrial fibrillation 47 (49%) 9 (53%) 17 (71%) 11 (55%) 0.316
NYHA class II 85 (89%) 7 (41%) 13 (54%) 11 (55%) < 0.001
NYHA class III 10 (11%) 10 (59%) 11 (46%) 9 (45%) < 0.001
HF Etiology
Hypertension 26 (27%) 1 (6%) 5 (21%) 3 (15%) 0.212
Ischemic heart disease 30 (32%) 7 (41%) 8 (33%) 9 (45%) 0.641
Dilated cardiomyopathy 8 (8%) 2 (12%) 1 (4%) 2 (10%) 0.768
Valve heart disease 15 (16%) 5 (29%) 4 (17%) 5 (25%) 0.439
Congenital 0 (0%) 1 (6%) 1 (4%) 1 (5%) 0.058
Others 16 (17%) 1 (6%) 5 (21%) 0 (0%) 0.110
Systolic BP (mmHg) 129 ± 18 118 ± 20 119 ± 21 114 ± 12 0.001
Diastolic BP (mmHg) 74 ± 12 67 ± 8 73 ± 14 71 ± 9 0.156
LVEF (%) 51 ± 16 46 ± 16 46 ± 22 38 ± 18 0.015
LVDD (mm) 54 ± 8 52 ± 9 56 ± 13 57 ± 11 0.290
LAD (mm) 49 ± 9 49 ± 9 51 ± 9 54 ± 12 0.184
IVS (mm) 12 ± 3 12 ± 2 13 ± 3 11 ± 3 0.158
LVPW (mm) 11 ± 2 10 ± 2 11 ± 2 10 ± 2 0.461
Na+ (mEq/dL) 140 ± 3 138 ± 4 140 ± 4 139 ± 5 0.227
K+ (mEq/dL) 4.2 ± 0.5 4.3 ± 0.6 4.4 ± 0.7 4.2 ± 0.5 0.453
GF (mL/min per 1.73 m2) 61 ± 20 62 ± 16 49 ± 22 53 ± 20 0.029
Hemoglobin (g/dL) 131 ± 20 118 ± 25 126 ± 21 129 ± 24 0.111

LVEF: Left ventricular ejection fraction; NYHA: New York Heart Association; HF: Heart failure; LVDD: Left ventricular diastolic diameter; LAD: Left auricular diameter; IVS: Interventricular septum; LVPW: Left ventricular posterior wall; BP: Blood pressure; Na: Sodium; K: Potassium; GF: Glomerular filtration; CA125: Carbohydrate antigen 125; NT-proBNP: N-terminal pro-B-type natriuretic peptide.